These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

202 related items for PubMed ID: 2567266

  • 1. Olsalazine or sulphasalazine in first attacks of ulcerative colitis? A double blind study.
    Rao SS, Dundas SA, Holdsworth CD, Cann PA, Palmer KR, Corbett CL.
    Gut; 1989 May; 30(5):675-9. PubMed ID: 2567266
    [Abstract] [Full Text] [Related]

  • 2. Double-blind comparison of olsalazine and sulphasalazine in active ulcerative colitis.
    Willoughby CP, Cowan RE, Gould SR, Machell RJ, Stewart JB.
    Scand J Gastroenterol Suppl; 1988 May; 148():40-4. PubMed ID: 2906476
    [Abstract] [Full Text] [Related]

  • 3. Controlled trial comparing olsalazine and sulphasalazine for maintenance treatment of ulcerative colitis.
    Jewell DP, Ireland A.
    Scand J Gastroenterol Suppl; 1988 May; 148():45-7. PubMed ID: 2906477
    [Abstract] [Full Text] [Related]

  • 4. Treatment of ulcerative colitis with olsalazine and sulphasalazine: efficacy and side-effects.
    Ewe K, Eckardt V, Kanzler G.
    Scand J Gastroenterol Suppl; 1988 May; 148():70-5. PubMed ID: 2906479
    [Abstract] [Full Text] [Related]

  • 5. Prophylactic effects of olsalazine v sulphasalazine during 12 months maintenance treatment of ulcerative colitis. The Danish Olsalazine Study Group.
    Kiilerich S, Ladefoged K, Rannem T, Ranløv PJ.
    Gut; 1992 Feb; 33(2):252-5. PubMed ID: 1347280
    [Abstract] [Full Text] [Related]

  • 6. Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis.
    Ireland A, Mason CH, Jewell DP.
    Gut; 1988 Jun; 29(6):835-7. PubMed ID: 2898422
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse.
    Riley SA, Mani V, Goodman MJ, Herd ME, Dutt S, Turnberg LA.
    Gut; 1988 May; 29(5):669-74. PubMed ID: 2899536
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Double-blind dose-finding study of olsalazine versus sulphasalazine as maintenance therapy for ulcerative colitis.
    Kruis W, Judmaier G, Kayasseh L, Stolte M, Theuer D, Scheurlen C, Hentschel E, Kratochvil P.
    Eur J Gastroenterol Hepatol; 1995 May; 7(5):391-6. PubMed ID: 7614099
    [Abstract] [Full Text] [Related]

  • 11. Olsalazine in the treatment of active ulcerative colitis: a placebo controlled clinical trial and assessment of drug disposition.
    Hetzel DJ, Shearman DJ, Labrooy J, Bochner F, Imhoff DM, Gibson GE, Fitch RJ, Hecker R, Rowland R.
    Scand J Gastroenterol Suppl; 1988 May; 148():61-9. PubMed ID: 3067339
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Clinical experience of the tolerance of mesalazine and olsalazine in patients intolerant of sulphasalazine.
    Rao SS, Cann PA, Holdsworth CD.
    Scand J Gastroenterol; 1987 Apr; 22(3):332-6. PubMed ID: 2884724
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Olsalazine versus sulfasalazine in mild to moderate childhood ulcerative colitis: results of the Pediatric Gastroenterology Collaborative Research Group Clinical Trial.
    Ferry GD, Kirschner BS, Grand RJ, Issenman RM, Griffiths AM, Vanderhoof JA, Fiedorek SC, Winter HS, Hassall EG, Watkins JB.
    J Pediatr Gastroenterol Nutr; 1993 Jul; 17(1):32-8. PubMed ID: 8102399
    [Abstract] [Full Text] [Related]

  • 18. 5-amino salicylic acid absorption and metabolism in ulcerative colitis patients receiving maintenance sulphasalazine, olsalazine or mesalazine.
    Stretch GL, Campbell BJ, Dwarakanath AD, Yaqoob M, Stevenson A, Morris AI, Rhodes JM.
    Aliment Pharmacol Ther; 1996 Dec; 10(6):941-7. PubMed ID: 8971292
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Systemic levels of free 5-aminosalicylic acid depend on the nature of the 5-aminosalicyclic acid derivative and not on disease activity or extent in patients with inflammatory bowel disease.
    Mahmud N, Weir DG, Kelleher D.
    Ir J Med Sci; 1999 Dec; 168(4):228-32. PubMed ID: 10624358
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.